MLTX - MoonLake Immunotherapeutics

17.89
-0.450   -2.515%

Share volume: 570,286
Last Updated: 04-20-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.17%

PREVIOUS CLOSE
CHG
CHG%
$18.34
-0.45
-0.02%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
41%
Profitability 35%
Dept financing 24%
Liquidity 50%
Performance 50%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
0.56%
1 Month
6.05%
3 Months
7.06%
6 Months
95.31%
1 Year
-55.28%
2 Year
-56.39%
Key data
Stock price
$17.89
P/E Ratio 
0.00
DAY RANGE
$17.83 - $18.47
EPS 
-$3.16
52 WEEK RANGE
$5.95 - $62.75
52 WEEK CHANGE
-$54.65
MARKET CAP 
846.561 M
YIELD 
N/A
SHARES OUTSTANDING 
71.728 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
08-06-2025
BETA 
1.44
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$862,838
AVERAGE 30 VOLUME 
$1,321,138
Company detail
CEO: Jorge Santos da Silva
Region: US
Website: moonlaketx.com
Employees: 2
IPO year: 2020
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, or ankylosing spondylitis.

Recent news